These key molecular initiating events with PPARα activation are central to the disruption of most pathways associated with obesity, diabetes, high cholesterol, and other metabolic-dysfunction-associated fatty liver diseases (MAFLDs). The gene discussed is PPARA; the disease is obesity due to melanocortin 4 receptor deficiency.